ANAB 241220 17.50C (ANAB241220C17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ANAB241220C17500

Watchlist

0.35
+0.14+66.67%

15min DelayClose Dec 13 16:00 ET

0.40High0.35Low

Intraday

5D
Daily

News

Wells Fargo Maintains Overweight on AnaptysBio, Lowers Price Target to $40
BenzingaDec 12 14:16 ET · Ratings
AnaptysBio Price Target Cut to $36.00/Share From $90.00 by Guggenheim
Dow JonesDec 12 10:32 ET · Ratings
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36
Moomoo NewsDec 12 08:31 ET · Ratings
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40
Moomoo NewsDec 12 06:31 ET · Ratings
Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity
TipRanksDec 12 06:05 ET · Ratings
AnaptysBio's Atopic Dermatitis Trial of BTLA Agonist Misses Endpoints
Yahoo FinanceDec 12 05:23 ET

Comments

Trytosaveabit

Dec 11 07:36

T1 news halt!

$AnaptysBio (ANAB.US)$ Reuters· 3 mins ago
AnaptysBio Inc - Anb032 Ad Trial and All Further Investment Will Be Discontinued

Jsmooth420365

Aug 31 22:56

$AnaptysBio (ANAB.US)$ looking good got smacked last timee it tested $40.. needs to break that on heavy volume 🤔

Jaguar8

May 9 15:54

$AnaptysBio (ANAB.US)$
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...

Jaguar8

May 9 15:53

$AnaptysBio (ANAB.US)$
NEWS
Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties

White_Shadow

May 1 10:43

$AnaptysBio (ANAB.US)$ Go baby go...